Supplement containing unlisted ED drug is recalled by manufacturer
The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.
The manufacturer of a sexual performance-enhancing supplement has announced a voluntary recall of the product, known as Liviro3. FDA lab analysis found the product contains the erectile dysfunction drug tadalafil, making Liviro3 an unapproved drug.
During the voluntary recall process, the manufacturer discovered a counterfeit of its product on the market. Both Liviro3 and the counterfeit supplement are undergoing renewed independent testing.
A bulletin issued by FDA cautions consumers who have either the genuine or counterfeit product in their possession to stop using it immediately and to contact their physician if they have experienced any problem that may be related to using either product.
Serious adverse events stemming from the use of Ebek’s Liviro3 or counterfeit Liviro3 should be reported to FDA’s MedWatch Adverse Event Reporting program online (www.fda.gov/MedWatch/report.htm) or by calling 800-FDA-1088.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
